Biopatent

Patents granted for biological entities and for products derived from them are called biopatents.

A patent is a special legal right granted by a government (through a Patent Office) to an inventor, giving them exclusive control over the commercial use of their invention for a defined period. A patent is legally treated as personal property – it can be sold, licensed, or transferred.

A patent document generally has three parts:

Patents may be granted for four categories of work:

• A new invention, including a product
• An improvement to an existing invention
• A new process for generating a product
• A new concept or design

A biopatent is a patent granted for a biological entity or for a product/process derived from a biological entity, giving the patent holder exclusive rights over its commercial use for a specific period.

Biopatents typically cover:

• Microorganism strains
• Cell lines
• Genetically modified (GM) strains
• DNA sequences
• Biotechnological processes and products

Why Biopatents Exist

• They reward inventors for the time, cost, and research effort behind a biological innovation.
• They encourage a scientific research culture within biotechnology.
• They highlight biology's growing economic and industrial importance in society.

• Grant private monopoly rights over biological materials and processes.
• Can restrict free sharing of biological resources and slow down collaborative research.
• Shift research priorities toward what is profitable/patentable rather than what is scientifically or socially needed.
• Can affect farmers' and communities' traditional access to biological resources.

Case Study 1: First Biopatent (India)

• A genetically engineered strain of Pseudomonas bacteria, capable of degrading oil, was the first biopatent case of significance, used for clearing oil spills.
• Why it matters: Demonstrates a legitimate, environmentally beneficial biopatent application.

Case Study 2: Basmati Rice Controversy

• A Texas-based company obtained US patent rights (via USPTO) on a rice variety derived by crossing Indian Basmati with a semi-dwarf rice variety.
• Why it matters: Widely cited as an example of biopiracy – commercial exploitation of a country's traditional biological resource without consent or benefit-sharing.

Case Study 3: Terminator Gene Technology

• A patent on "control of plant gene expression" technology (linked to Delta & Pine Land Company and the USDA) was not granted in India.
• Why it matters: Rejected on ethical and food-security grounds, since the technology could prevent farmers from saving and replanting seeds.

• A biopatent is a special legal right granted to an inventor that provides exclusive commercial control over a biological entity or its derived products for a specific period.
• These patents specifically cover biological components such as microorganism strains, cell lines, DNA sequences, genetically modified strains, and biotechnological processes.
• A standard patent document is structured into three specific parts: the legal grant, the detailed technical specification, and the specific claims of protection.
• In India, patent laws permit process patents for the methods used to create biological materials but strictly prohibit product patents for the biological materials themselves.
• The first significant biopatent was awarded for an environmentally beneficial, genetically engineered strain of Pseudomonas bacteria capable of degrading oil spills.
• The controversial US patent granted for a rice variety derived from Indian Basmati serves as a major example of biopiracy and the commercial exploitation of traditional resources.
• India actively rejects certain biopatents on ethical and food-security grounds, such as denying terminator gene technology because it would prevent farmers from saving and replanting seeds.